By the Leanova Research Team
GLP-1 medicines such as semaglutide and tirzepatide are usually discussed in terms of kilos lost or blood sugar improved. But a newer question is now being asked by economists and employers: does treating obesity and metabolic disease change how people work? A recent CNBC Make It feature, "How GLP-1s Are Reshaping The Workforce", brought several of these studies together. We read the original research so you don't have to, and here is what it actually says, including where the headlines go further than the data.
How common are GLP-1 medicines now?
In the United States, a Gallup survey of over 5,000 adults (May–June 2026) found that 11% currently take a GLP-1 medicine for weight loss, up from 3% in 2024. This is self-reported survey data from one country, so it says little about India directly. What it does show is how quickly these medicines have moved into everyday life, and why workplaces are paying attention.
In India, obesity, prediabetes and type 2 diabetes often appear at lower body weights than in Western populations, and many of our patients are working professionals juggling long hours, travel and family responsibilities. So the question "will this help me function better at work?" is a fair one to ask.
Finding 1: Less long-term sick leave (Denmark)
The strongest evidence so far comes from a 2026 National Bureau of Economic Research working paper by Daysal and colleagues, which used Denmark's national health and employment records. They compared people who started GLP-1 treatment early, when semaglutide first became available, with similar people who started about four years later.
What they found:
- Long-term sickness leave (absences over 30 days) fell by about 17% — from a baseline of 5.5% to roughly 4.6%, an absolute drop of about 1 percentage point.
- The effect built gradually over four years, alongside fewer emergency visits and less cardiovascular medication use.
- There was no meaningful change in employment, income or labour-force participation.
Our honest read: this is a careful observational study, not a randomised trial, and it has not yet been peer-reviewed. It suggests that better metabolic health may help some people avoid serious health events that keep them off work. It does not show that GLP-1s make people earn more or get promoted. The authors themselves caution that results from Denmark's welfare system may not carry over to other countries.
Finding 2: Employment changes among women (USA)
A second working paper, by Harvard economist Rebecca Diamond (NBER, 2026), followed women in the Understanding America Study. Women who were not employed when they started a GLP-1 for weight loss were about 27 percentage points more likely to be employed after 18 months or more, compared with women who wanted the medicine but hadn't started it. Women who were already employed showed no rise in hours, income or job moves.
Our honest read: this is an interesting but small, survey-based, non-randomised, not-yet-peer-reviewed study, with wide uncertainty around the numbers. It cannot prove the medicine caused the job gains. The author's interpretation is that weight bias may matter most at the "first impression" stage, such as interviews. That links to a much larger body of research on weight stigma.
The uncomfortable part: weight stigma
Decades of research show that people living with larger bodies face bias in hiring, pay and healthcare, and that women tend to bear more of it. A widely cited review by Puhl and Heuer documented this across employment, education and medical settings.
We want to be clear: obesity is a chronic, biological condition, not a failure of willpower. Nobody should feel they need medication to "deserve" a job. The right reason to consider treatment is your health: blood sugar, blood pressure, liver fat, joint pain, sleep apnoea, energy and long-term heart risk. Any confidence or work benefit is welcome, but it's a bonus, not a promise.
What we know more firmly: the health evidence
The work findings rest on stronger clinical foundations:
- In the STEP 1 randomised trial (NEJM, 2021), adults with obesity on semaglutide 2.4 mg plus lifestyle support lost on average about 15% of body weight over 68 weeks, versus about 2.4% with placebo.
- In the SELECT randomised trial (NEJM, 2023), semaglutide reduced major cardiovascular events by about 20% in people with overweight or obesity and existing heart disease (but without diabetes).
These are averages. Individual results vary a lot, and weight often returns when the medicine is stopped unless habits and follow-up are in place.
Risks and side effects you should know
GLP-1 medicines are not for everyone and must be prescribed and monitored by a doctor. Common side effects include nausea, vomiting, diarrhoea, constipation, reflux and reduced appetite, usually worst when starting or increasing the dose. Less common but important risks include gallbladder problems, pancreatitis, dehydration-related kidney strain, and loss of muscle if protein intake and strength training are neglected. They are not advised in pregnancy, or for people with a personal or family history of certain thyroid cancers (medullary thyroid carcinoma or MEN2). Buying these medicines without a prescription, or from unverified sources, is unsafe.
What this means for you
If you are considering treatment, think of these studies as an encouraging signal, not a guarantee. A good programme should include:
- A full medical assessment (blood tests, HbA1c, liver, kidney and thyroid checks) by an NMC-registered physician.
- A personalised plan for nutrition, protein, movement and sleep, which matter whether or not medicine is used.
- Regular follow-up to manage side effects and adjust the plan safely.
Frequently asked questions
Will a GLP-1 medicine help my career? There is no reliable evidence that it will. One Danish study linked treatment with less long-term sick leave, but not with higher income or employment.
Are these studies proven? Both labour-market studies are observational working papers not yet peer-reviewed. The weight-loss and heart benefits come from large randomised trials, which are stronger evidence.
Can I take a GLP-1 without seeing a doctor? No. These are prescription medicines that need proper screening and monitoring.
Do Indian patients respond the same way? Most trials included few South Asian participants. A doctor will tailor treatment to your health profile, since metabolic risk in Indians often starts at a lower BMI.
Talk to us
If you would like to understand whether metabolic treatment is right for you, our NMC-registered physicians can help. WhatsApp: +91 93633 43330 · Email: care@leanova.in · Web: leanova.in
Medical disclaimer: This article is for general education only and is not medical advice. It does not replace a consultation with a qualified doctor. Results vary between individuals and no outcome is guaranteed. Please consult a doctor before starting, stopping or changing any medication.
References
- Gallup. "In U.S., GLP-1 Usage Reaches New High." Gallup National Health and Well-Being Index, 2026 (survey of 5,065 US adults). https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx — cross-sectional survey
- Daysal NM, Fredrickson CJH, Kristiansen IL, Trandafir M, Zhang J. "The Labor Market Impacts of GLP-1s." NBER Working Paper 35475, 2026. https://doi.org/10.3386/w35475 — human observational (registry, difference-in-differences); not peer-reviewed
- Diamond R. "GLP-1–Induced Weight Loss and the Female Obesity Penalty." NBER Working Paper 35387, 2026. https://www.nber.org/papers/w35387 — human observational (survey panel, matched comparison); not peer-reviewed
- Puhl RM, Heuer CA. "The Stigma of Obesity: A Review and Update." Obesity, 2009;17(5):941–964. https://doi.org/10.1038/oby.2008.636 — narrative review
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). New England Journal of Medicine, 2021;384:989–1002. https://doi.org/10.1056/NEJMoa2032183 — RCT
- Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes" (SELECT). New England Journal of Medicine, 2023;389:2221–2232. https://doi.org/10.1056/NEJMoa2307563 — RCT
- CNBC Make It. "How GLP-1s Are Reshaping The Workforce." YouTube video. https://youtu.be/5zs1ze3P7Oc